India’s Top 25 Pharma Companies by Revenue in 2026: Unveiling the Giants of the Pharmaceutical Industry

1) Sun Pharma

Sun Pharma, topping the list of India’s highest-grossing pharma companies, has delivered a robust financial performance in the most recent reporting period. With a continued focus on both specialty and generic products, the company reported a latest quarterly revenue of approximately ₹14,478 crore, reflecting strong momentum across key therapeutic segments. Notably, its operations in the US market contributed around $495 million (about ₹4,537.94 crore), underlining the strategic importance of the region and showcasing steady year-on-year growth driven largely by specialty products.

Research and development continues to be a cornerstone of Sun Pharma’s strategy, with multiple new molecules currently under clinical development for various conditions, including diabetes, dermatology, and oncology. This sustained investment in innovation positions the company to strengthen its future product pipeline.

The company’s success in the Indian market remains particularly notable, with a substantial portion of revenue derived from domestic sales, indicating strong local demand. The overall positive outlook from analysts suggests that Sun Pharma’s balanced focus on both the Indian and international markets is likely to sustain its growth and profitability in the foreseeable future.

2) Dr. Reddy’s Labs

Dr. Reddy’s Laboratories, a significant player in the Indian pharmaceutical landscape, reported total revenues of approximately ₹34,682.20 crore in the most recent reporting period. The company experienced moderate growth, fueled by strategic pricing, innovative product launches, and a strong presence in both emerging and regulated markets. Dr. Reddy’s Labs also focused on enhancing its research and development activities, leading to new opportunities in small molecules and biosimilars. The company’s financial stability is reflected in its consistent investment in technology and ongoing global expansion efforts.

3) Aurobindo Pharma

Aurobindo Pharma, headquartered in Hyderabad, is a prominent player in the Indian pharmaceutical sector. In the most recent reporting period, Aurobindo Pharma reported net sales of approximately ₹32,514.48 crore, reflecting its continued strength and scale. The company has shown a commendable performance, maintaining a significant presence across both domestic and international markets.

Aurobindo Pharma specializes in producing generic pharmaceuticals and active pharmaceutical ingredients (APIs), catering to various therapeutic categories such as neurosciences, cardiovascular, antiretrovirals, antibiotics, and gastroenterology. The company’s robust product portfolio continues to support its strong position in the competitive pharmaceutical landscape.

Over recent quarters, Aurobindo Pharma has demonstrated steady financial momentum. In the latest reported quarter, the company recorded revenue of around ₹7,900 crore, reflecting healthy year-on-year growth driven by demand in regulated markets and operational efficiencies. Net profit for the quarter also showed a sharp improvement, supported by better margins and improved product mix.

Aurobindo’s consistent focus on expanding its global footprint and strengthening its manufacturing capabilities has played a crucial role in its growth trajectory, further solidifying its position among the leading pharmaceutical companies in India.

4) Cipla

Cipla continues to stand out in India’s pharmaceutical industry with strong financial performance in the most recent reporting period, maintaining its position as one of the leading companies in the sector. The company reported revenues of approximately ₹28,351.08 crore, supported by robust sales across its branded prescription, trade generics, and consumer health segments. Notably, Cipla’s strategic initiatives in the US market, along with new product launches, have contributed meaningfully to this performance.

Cipla’s commitment to research and development remains a key focus, driving the introduction of new products and enhancing its market competitiveness. The company has also demonstrated solid traction in emerging markets, further strengthening its global presence. This balanced approach to growth across multiple segments of the pharmaceutical market underscores Cipla’s continued emphasis on innovation and international expansion.

5) Lupin

Lupin has demonstrated steady growth in the most recent reporting period, reinforcing its position as a key player in both the Indian and global pharmaceutical markets and coming to 5th positon by taking lead From Zydus life from previous year. In the latest reported quarter, Lupin recorded net sales of approximately ₹6,300 crore, reflecting continued improvement compared to the same period last year.

Lupin’s strategic initiatives across key geographies have contributed meaningfully to this performance. Sales in North America continued to show strong traction with healthy year-on-year growth, driven by new launches and improved product mix, indicating sustained demand for Lupin’s offerings in the region. The company also reported solid growth in the Indian market, supported by branded formulations and strong execution, underscoring its domestic strength.

Research and development remains a critical focus for Lupin, with R&D investments of around ₹4,500 million, accounting for roughly 7–8% of sales, highlighting the company’s continued commitment to innovation and pipeline expansion. These investments have translated into multiple ANDA approvals and new product launches in the US, strengthening its generics portfolio.

Overall, Lupin’s recent performance reflects successful execution across markets, operational efficiencies, and sustained emphasis on R&D, positioning the company well for continued growth in the coming periods.

6) Zydus Life

Zydus Life, previously known as Zydus Cadila, has continued to deliver a strong performance in the most recent reporting period, particularly across its India and US markets. The company reported consolidated revenues of approximately ₹5,600 crore in the latest quarter, reflecting healthy year-on-year growth supported by improved product mix and market traction. The US formulations business remained a key contributor, generating around ₹2,500 crore, driven by specialty launches and steady demand, even as quarterly performance fluctuated due to product launch timing.

In the Indian market, the formulations business recorded revenues of about ₹1,600 crore, supported by strong growth in branded formulations, especially in anti-diabetic and respiratory therapies. The consumer wellness segment, which includes well-known brands such as Nycil and EverYuth, also delivered solid growth, aided by favorable seasonal demand and brand-led momentum.

Zydus Life continues to actively expand its product offerings and advance its innovation pipeline. The company has made notable progress in research and development, including ongoing clinical trials for new chemical entities targeting neurological and cardiovascular conditions, reinforcing its long-term focus on innovation and differentiated therapies.

7) Biocon

Biocon remains a major name in India’s pharmaceutical and biopharma space, reporting total revenues of approximately ₹16,475.80 crore in the most recent reporting period. Supported by its strong presence in biosimilars, generics, and research services, the company has continued to demonstrate stable and resilient performance.

In the latest reported quarter, Biocon recorded revenues of around ₹4,000 crore, reflecting steady year-on-year growth. This performance was driven largely by rising demand for its biosimilar portfolio and continued expansion across global and regulated markets.

Biocon continues to invest significantly in research and development to advance innovative and affordable therapies worldwide. With ongoing product launches, strategic partnerships, and an expanding global footprint, the company remains focused on strengthening its position and driving sustainable growth in the coming periods.

9) Alkem Lab

Alkem Laboratories, an esteemed player in the Indian pharmaceutical industry, has reported significant financial achievements for the fiscal year 2025. In the third quarter, Alkem’s total revenue from operations reached ₹3,374.28 crore, with a marginal growth of 1.5%. This robust growth trajectory was further underscored in their nine-month performance, with a total revenue of ₹98,208 million, showing a 0.9% increase compared to the same period in the previous year.

Alkem Laboratories has excelled in harnessing strategic market opportunities and expanding its product portfolio, which includes branded generics, generic drugs, active pharmaceutical ingredients (APIs), and nutraceuticals. Their strong performance is partly attributed to significant revenue boosts from both domestic and international markets, reflecting the company’s effective global expansion strategy and its adaptability to dynamic market demands.

Continued focus on R&D and strategic marketing initiatives has also played key roles in driving Alkem’s growth, allowing it to maintain a competitive edge in the pharmaceutical sector. This concerted effort towards innovation and global market penetration is indicative of Alkem’s commitment to enhancing healthcare outcomes worldwide.

10) Mankind Pharma

Mankind Pharma is renowned for its wide range of pharmaceutical and healthcare products, focusing on over-the-counter and prescription medications across various therapeutic areas. Known for its consumer-friendly products in the Indian market, the company excels in sectors such as antibacterials, antidiabetics, and cardiovascular drugs. In the most recent reporting period, Mankind Pharma reported revenues of approximately ₹13,545.67 crore, reflecting its strong market reach and continued commitment to affordable healthcare solutions, which contribute significantly to its growth.

11) Torrent Pharma

Torrent Pharma is recognized for its strong focus on the therapeutic areas of cardiovascular, central nervous system, gastrointestinal, and anti-inflammatory drugs. With a robust presence in both the Indian and global markets, the company is known for its integrated healthcare solutions. In the most recent reporting period, Torrent Pharma generated revenues of approximately ₹12,248 crore, demonstrating its operational strength and continued innovation in drug development, which have played a key role in sustaining its growth and market penetration.

12) Divis Labs

Divi’s Labs specializes in the production of APIs and intermediates, with a strong focus on high-potency compounds and nutraceutical ingredients. The company is renowned for its high-quality standards and innovation in the pharmaceutical manufacturing sector. In the most recent reporting period, Divi’s Labs reported revenues of approximately ₹10,029 crore, driven by its expertise in complex chemistries and its strategic positioning as a crucial partner for global pharmaceutical companies.

13) Ipca Labs

Ipca Labs is highly regarded for its manufacturing and supply of various pharmaceutical products, particularly specializing in APIs and generic formulations. The company has a strong presence in therapeutic segments such as pain management, antimalarials, and cardiovascular drugs. In the most recent reporting period, Ipca Labs reported revenues of approximately ₹9,357.41 crore, illustrating its robust performance and strategic market expansion, underpinned by its significant contribution to essential medicines and its continued commitment to quality and affordability in healthcare.

14) Piramal Pharma

Piramal Pharma is distinguished by its engagement in contract development and manufacturing, critical care, and the development of complex hospital generics. The company’s approach to leveraging strategic partnerships and focusing on niche markets has established its reputation within the pharmaceutical industry. In the most recent reporting period, Piramal Pharma reported revenues of approximately ₹8,935.72 crore, highlighting its continued expansion and innovative contributions to healthcare solutions.

15) Emcure Pharma

Emcure Pharmaceuticals has continued to deliver a solid financial performance in the most recent reporting period, reporting total revenues of approximately ₹8,449.24 crore. The company has steadily strengthened its presence across both domestic and international markets, supporting its overall growth momentum.

In the latest reported quarter, Emcure recorded revenues of around ₹2,200 crore, reflecting healthy year-on-year growth driven by improved demand and operational efficiency. The company’s profitability also showed improvement, highlighting the strength of its core operations and execution.

Emcure’s domestic business remained a key contributor, supported by consistent growth in branded formulations, while its international segment continued to expand at a faster pace, driven by increasing traction in regulated and emerging markets. Operating performance remained stable, supported by disciplined cost management and scale benefits.

With a continued focus on expanding its product portfolio, investing in research and development, and strengthening its global footprint, Emcure Pharmaceuticals remains well positioned for sustained growth and long-term success in the pharmaceutical industry.

16) Jubilant Pharmova

Jubilant Pharmova, a leading player in the pharmaceutical and life sciences industry, reported revenues of approximately ₹7,617.60 crore in the most recent reporting period. In the latest quarter, the company recorded revenues of around ₹1,900 crore, reflecting healthy year-on-year growth, while net profit stood at about ₹100 crore, highlighting improved operational performance. With a strong presence in radiopharmaceuticals, contract manufacturing, and generics, Jubilant Pharmova continues to expand its global footprint, with a sustained focus on innovation and specialized healthcare solutions.